These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21947806)

  • 1. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C; Harris J; Sulston J; Spanswick C
    J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 3. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 4. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

  • 5. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 6. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 9. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 10. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescribing bevacizumab off-label contravenes GMC advice.
    Kyle G
    BMJ; 2011 Nov; 343():d7131. PubMed ID: 22077076
    [No Abstract]   [Full Text] [Related]  

  • 12. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
    ; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC
    Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA; Kim SJ
    Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 15. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.
    Ahfat FG; Zaidi FH
    Eye (Lond); 2013 Mar; 27(3):289-90. PubMed ID: 23485959
    [No Abstract]   [Full Text] [Related]  

  • 17. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 18. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 19. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.